Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors

Cancer Biology and Therapy

Volumn 12, Issue 2, 2011, Pages 139-151

  Dabir, Snehal ^a   Kluge, Amy ^a   Aziz, Mohammad A ^b   Houghton, Janet A ^b   Dowlati, Afshin ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

EGR; Epidermal growth factor; Lung cancer; PIAS3; Signal transduction; STAT3; Transcription factor

Indexed keywords

BETA CATENIN; PROTEIN INHIBITOR OF ACTIVATED SIGNAL TRANSDUCER AND ACTIVATORS OF TRANSCRIPTION 3; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ERG 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NR1I2; UNCLASSIFIED DRUG; WNT PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT3; TRANSCRIPTION FACTOR EGR 1; CHAPERONE; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; GATA1 PROTEIN, HUMAN; PIAS3 PROTEIN, HUMAN; PREGNANE X RECEPTOR; SMALL INTERFERING RNA; STEROID RECEPTOR; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG SQUAMOUS CELL CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; APOPTOSIS; CELL LINE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

APOPTOSIS; CELL LINE; CELL PROLIFERATION; EARLY GROWTH RESPONSE PROTEIN 1; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR CHAPERONES; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTORS, STEROID; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 79960390329     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.2.15732     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statisticsm 2009. CA Cancer J Clin 2009;59:225-49.
2. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742-51.
3. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62. (Pubitemid 34987786)
4. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54. (Pubitemid 35177340)
5. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003; 22:4150-65. (Pubitemid 36876236)
6. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 2004;3:459-63. (Pubitemid 39193723)
7. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278:1803-5. (Pubitemid 27527648)
8. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005; 5:593-605. (Pubitemid 41113191)
9. Ohshima T, Shimotohno K. Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4. J Biol Chem 2003; 278:50833-42. (Pubitemid 38020313)
10. Liu B, Yang R, Wong KA, Getman C, Stein N, Teitell MA, et al. Negative regulation of NFkappaB signaling by PIAS1. Mol Cell Biol 2005; 25:1113-23. (Pubitemid 40165817)
11. Gross M, Yang R, Top I, Gasper C, Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 2004; 23:3059-66. (Pubitemid 38648196)
12. Long J, Wang G, Matsuura I, He D, Liu F. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci USA 2004; 101:99-104. (Pubitemid 38084210)
13. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008; 14:4694-704.
14. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol 2011; In print.
15. Dabir S, Kluge A, Dowlati A. The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. Mol Cancer Res 2009;7:1854-60.
16. Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, et al. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer 2009; 125:1728-34.
17. O'Connell MP, Fiori JL, Kershner EK, Frank BP, Indig FE, Taub DD, et al. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells. J Biol Chem 2009; 284:28704-12.
18. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2009.
19. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002; 2:8.
20. Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment - where there's SPARC, there's fire. J Cell Biochem 2008; 104:721-32. (Pubitemid 351830824)
21. Jang HD, Yoon K, Shin YJ, Kim J, Lee SY. PIAS3 suppresses NFkappaB-mediated transcription by interacting with the p65/RelA subunit. J Biol Chem 2004;279:24873-80. (Pubitemid 38725356)
22. Levy C, Nechushtan H, Razin E. A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor. J Biol Chem 2002; 277:1962-6. (Pubitemid 34968775)
23. Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T. Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann Oncol 2002; 13:1598-604. (Pubitemid 35331457)
24. Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 2002; 5:150-8. (Pubitemid 34453253)
25. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102:981-6. (Pubitemid 36917793)
26. Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Mol Cell Biol 1995; 15:6262-72.
27. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997;272:20131-8. (Pubitemid 27340120)
28. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102-9. (Pubitemid 27314646)
29. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, et al. Expression patterns of immediate early transcription factors in human nonsmall cell lung cancer. The Lung Cancer Study Group. Oncogene 1995; 11:1261-9.
30. Calogero A, Cuomo L, D'Onofrio M, de Grazia U, Spinsanti P, Mercola D, et al. Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. Oncogene 1996; 13:2105-12. (Pubitemid 26411560)
31. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000; 275:20315-23. (Pubitemid 30457606)
32. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004; 23:6170-4. (Pubitemid 39178870)